CenterWatch

Clinical Trial Details

Overview

Research Study Summary

Study to confirm the efficacy of Fesoterodine 4 mg compared to 8 mg.

Purpose

The purpose of this study is to compare the effectiveness of two doses of a drug called Fesoterodine and placebo (a substance that contains no active ingredient but looks identical to the study drug) for overactive bladder. In order to achieve this evaluation in an unbiased manner, you will be randomly assigned to one of 3 groups: Fesoterodine 4 mg, Fesoterodine 8 mg, or Placebo.

Patient Inclusion Criteria:

  • Male or female over the age of 18
  • Overactive bladder for over 6 months
  • Subject must LEAK

Patient Exclusion Criteria:

  • A neurological condition
  • History of lower urinary tract or pelvic surgery
  • History of IC, bladder stones, or urinary retention
  • Bladder outlet obstruction

To Learn more

CW ID: 180155
Date Last Changed: May 2, 2014

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
18 and up
Overall Status
Recruiting
Facility Type
N/A

Contact

Kristen Willinger, Research Recruiter
First Urology, PSC
101 Hospital Blvd
Jeffersonville, IN 47130
Phone: (812) 206-8166
Fax: (812) 288-2612

View Map

Research Center Information: First Urology, PSC

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.